Sanofi/Ad Scientiam presented an interim analysis from the ongoing MS-DETECT (NCT05816122) study at the 12th Congress of the European Academy of Neurology (EAN) 2026, showing that Microsoft (MS) Copilot can monitor disease progression in patients with multiple sclerosis (MS). The multi-centre trial across the US, Canada, and Europe has 336 patients enrolled. The data was presented during an oral session on 28 June. The interim analysis showed that MS Copilot Detect scores correlated with the MSFC-4 framework when performed in clinic or independently by the patient at home, including assessments of walking capacity, cognitive processing speed, upper-limb fine dexterity, and low-contrast visual acuity. The correlation was conserved over a 12-month period. The MS-DETECT study is one of the first pivotal trials investigating digital biomarkers. While MS Copilot Detect has shown promise as a tool for remote MS monitoring using patients' smartphones, full results are needed to assess long-term adherence and patient attrition rates. Further validation against established biomarkers, such as blood and cerebrospinal fluid biomarkers like glial fibrillary acidic protein and neurofilament light chain, or imaging biomarkers, is required.